1,800
Participants
Start Date
December 30, 2023
Primary Completion Date
November 1, 2025
Study Completion Date
December 1, 2026
Urokinase
administered intravenously
Alteplase
administered intravenously
NOT_YET_RECRUITING
Sanya People's Hospital, Sanya
NOT_YET_RECRUITING
The First Affiliated Hospital of Jiamusi University, Jiamusi
NOT_YET_RECRUITING
Huiji District People's Hospital, Zhengzhou
NOT_YET_RECRUITING
The People's Hospital of Anyang City, Anyang
NOT_YET_RECRUITING
Pingdingshan The Second People's Hospital, Pingdingshan
NOT_YET_RECRUITING
The Second People's Hospital of Mengjin District, Luoyang
NOT_YET_RECRUITING
Kaifeng Central Hospital, Kaifeng
NOT_YET_RECRUITING
Affiliated Hospital of Guangdong Medical University, Zhanjiang
NOT_YET_RECRUITING
Red Cross Hospital of Yulin City, Yulin
NOT_YET_RECRUITING
The First People's Hospital of Yulin, Yulin
NOT_YET_RECRUITING
Beiliu People's Hospital, Beiliu
NOT_YET_RECRUITING
Tengxian People's Hospital, Wuzhou
NOT_YET_RECRUITING
Guidong People's Hospital of Guangxi zhuang Autonomous Region, Guidong
NOT_YET_RECRUITING
The First People's Hospital of Lanzhou City, Lanzhou
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
NOT_YET_RECRUITING
Affiliated Hospital of Inner Mongolia Minzu University, Tongliao
Techpool Bio-Pharma Co., Ltd.
INDUSTRY
The First Affiliated Hospital of Zhengzhou University
OTHER